Translarna AdCom Has DMD Experience, But Most Opposed Approval Of Prior Applications

 
• By Derrick Gingery

Several members of the Peripheral and Central Nervous System Drugs Advisory Committee meeting looking at PTC' Therapeutics' proposed Duchenne muscular dystrophy treatment also looked at Sarepta's Exondys 51 and BioMarin's Kyndrisa, but most did not vote or comment favorably.

FDA Advisory Committee Feature image
Advisory committee members will review another proposed Duchenne muscular dystrophy drug on Sept. 28.

More from US FDA Performance Tracker

More from Regulatory Trackers